BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Lilly’s retatrutide shows solid weight loss, reduced knee pain
Eli Lilly and Co.’s latest phase III results for the obesity and overweight populations suggest its triple agonist, retatrutide, can deliver significant weight loss that,...

More in BioWorld

BioWorld MedTech

Flow Neuro wins FDA nod for at-home device for depression
Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses mild...

More in BioWorld MedTech

BioWorld Science

Epilepsygtx's $33M advances focal epilepsy gene therapy
Epilepsygtx Ltd. has raised a $33 million series A to fund a phase I/IIa trial of EPY-201, a gene therapy for treating drug-resistant focal epilepsy. EPY-201 uses an...

More in BioWorld Science

BioWorld Asia

Immutep shares rocket on AU$528M deal with Dr. Reddy’s
Immutep Ltd.’s stock surged 31% on Tuesday morning following the news that it out-licensed rights to Dr. Reddy’s Laboratories Ltd. to develop and commercialize eftilagimod...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.